Corporate Presentation

Obesity Survodutide The Phase 3 program with survodutide in obesity, SYNCHRONIZE™, has been initiated SYNCHRONIZETM-11 Efficacy and safety in patients with obesity without T2DM Inclusion criteria Study design • HbA1c <6.5% (no history of diabetes) BMI ≥30 or BMI ≥27 with comorbiditiesa • N=600 • 1:1:1 ratio (3.6 mg, 6.0 mg, or placebo) SYNCHRONIZETM-22 Efficacy and safety in patients with obesity and T2DM HbA1c ≥6.5% and <10% BMI ≥27 T2DM managed with diet and exercise alone or with stable pharmacological treatment SYNCHRONIZETM-CVOT3 Long-term CV safety in patients with obesity and established CVD/CKD or risk factors for CVD · BMI ≥27 with CVD and/or at least two weight-related risk factors for CVD, or • BMI ≥30 with CVD/CKD and/or at least two weight-related factors for CVD • Trial duration: 76 weeks ZEAL& ZEALAND PHARMA Boehringer Ingelheim Primary endpoint • Percentage change in body weight from baseline to Week 76 Achievement of body weight reduction ≥5% from baseline to Week 76 • N=600 • 1:1:1 ratio (3.6 mg, 6.0 mg or placebo) • • Trial duration: 76 weeks • N=4,935 • 1:1:1 ratio (3.6 mg, 6.0 mg or placebo) • Trial duration: up to 114 weeks Percentage change in body weight from baseline to Week 76 Achievement of body weight reduction ≥5% from baseline to Week 76 • Time to first occurrence of any of five major adverse cardiac events (5P-MACE) to demonstrate non- inferiority aComorbidities comprise dyslipidemia, hypertension, obstructive sleep apnea, and others. Inclusion criteria for all three trials include age ≥18 years. 5P-MACE includes cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, ischemia-related coronary revascularization or heart failure. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). Sources: 1. SYNCHRONIZE-1. ClinicalTrials.gov (NCT06066515), accessed November 2023; 2. SYNCHRONIZE-2. ClinicalTrials.gov (NCT06066528), accessed November 2023; 3. SYNCHRONIZE-CVOT. ClinicalTrials.gov (NCT06077864), accessed November 2023. BMI-body mass index; CKD=chronic kidney disease; CV-cardiovascular; CVD-cardiovascular disease; CVOT=cardiovascular outcomes trial; HbA1c=hemoglobin A1c; T2DM-type 2 diabetes mellitus. 29 29

View entire presentation